Efficacy And Safety Of Delafloxacin For The Treatment Of Acute Bacterial Skin And Skin Structure Infections:Meta-analysis Of Randomized Controlled Trials

Objective: To evaluate the clinical efficacy and safety of delafloxacin in the treatment of acute bacterial skin and skin structure infections.Methods: Pub Med database,EMbase database,Cochrane Library database and CNKI,CBM,WANFANG database were searched respectively.The contents were limited to randomized controlled trials of dalafloxacin in the treatment of acute bacterial skin and skin structural infections.Use Rev Man 5.3 software to analyze the clinical efficacy and adverse drug reaction rates in a meta-analysis.Result: A total of 4 clinical trial articles involving 1916 patients with acute bacterial skin and skin structure infection were included.The result in the early clinical response showed that(RR = 1.03,95%CI = [0.96,1.12],Z = 0.87,P = 0.38).The results of bacterial clearance rate(RR = 1.01,95%CI = [0.96,1.06],Z = 0.24,P=0.81)showed no significant difference compared with the control group.So the experimental group was non-inferior compared with control group.Meta-analysis showed that there was no differences in odds of clinical response were observed between delafloxacin and other comparators.The result for gastrointestinal disorders in its safety was(RR = 0.97,95%CI = [0.47,2.03],Z = 0.07,P =0.95),and the adverse reactions of nausea,vomiting and diarrhea were(RR = 0.90,95%CI =[0.45,1.81],Z = 0.29,P = 0.77),(RR = 0.70,95%CI = [0.17,2.99],Z = 0.47,P = 0.63)and(RR = 2.34,95%CI = [1.57,3.47],Z = 4.21,P<0.0001).The results showed that there was no significant difference in the incidence of adverse reactions in nausea and vomitingevents between the two groups,but the incidence of diarrhea events was higher in experimental group.In nervous system disorders,the incidence of delafloxacin group was lower(RR = 0.47,95%CI = [0.31,0.72],Z = 3.50,P = 0.0005).At last,there was no evidence of a difference among treatments for the incidence of severe adverse reactions and other adverse reactions in the treatment.Conclusion: The clinical efficacy,bacterial clearance rate and adverse reaction rate of delafloxacin in the treatment of ABSSSI were similar to that of control groups.However,due to the short time to market for delafloxacin,there are few clinical studies for long-term observation,and we still need to carry out more randomized controlled trials to support this conclusion.